Ilios Therapeutics
Skip to content
Ilios Therapeutics

Harvard Innovation Labs

Ilios Therapeutics

Combating neurodegenerative diseases through rationally-designed multi-functional small molecules.

Founders

Luca Giani

Harvard Business School, Harvard Kennedy School

Fares Nigim

Harvard Medical School

About Ilios Therapeutics

Term

2024 Spring

School

Harvard Business School, Harvard Medical School, Harvard Kennedy School

Programs

Blavatnik Fellowship

Connect

Email, Website, LinkedIn

Ilios has built a chemistry platform to generate multi-functional, brain-penetrant small molecules rationally-designed to combat neurodegenerative diseases. Our first-in-class therapeutics are designed to synergistically address the three key mechanisms driving neurodegenerative diseases: oxidative stress, brain inflammation, and protein misfolding. Our first program is on Amyotrophic Lateral Sclerosis (ALS), with plans to expand our therapeutic pipeline to include treatments for Parkinson's and Alzheimer's diseases.